Sugi Predict

Sugi Predict / Compounds / SCHEMBL207125

SCHEMBL207125

SCHEMBL207125

Cc1ccc2s[c]cc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 4/20 0.44
▸ CYP1A2 P05177 4/20 0.44
▸ TDP1 Q9NUW8 3/20 0.38
▸ CYP3A4 P08684 2/20 0.34
▸ TP53 P04637 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ ALOX15 P16050 2/20 0.34
▸ THRB P10828 1/20 0.34
▸ ALDH1A1 P00352 6/20 0.33
▸ MAPT P10636 2/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ ACHE P22303 1/20 0.32
▸ HSD17B10 Q99714 2/20 0.31
▸ NCK1 P16333 1/20 0.31
▸ BACE1 P56817 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ DYRK1A Q13627 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207027 0.83 CYP2A6 (0.44) CYP2A6CYP1A2TDP1CYP3A4TP53
SCHEMBL208842 0.74 CYP1A2 (0.38) CYP2A6CYP1A2TDP1ALDH1A1MAPT
SCHEMBL20895113 0.74 ALDH1A1 (0.38) TDP1CYP3A4TP53SMN1; SMN2ALOX15
SCHEMBL145983 0.74 HSP90AA1 (0.39) CYP2A6TDP1ALDH1A1MAPTRAB9A
SCHEMBL7235008 0.74 CLK1 (0.39) CYP1A2TDP1CYP3A4ALOX15MAPT
SCHEMBL385641 0.74 BACE1 (0.49) CYP2A6CYP1A2TDP1CYP3A4THRB
SCHEMBL467025 0.74 CYP2A6 (0.44) CYP2A6CYP1A2SMN1; SMN2ALDH1A1MAPT
SCHEMBL169044 0.73 — —
SCHEMBL851944 0.71 — —
SCHEMBL5535942 0.70 NQO1 (0.43) CYP1A2TDP1CYP3A4TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118164975-A Quaternary ammonium salt oxazolidinone derivative and pharmaceutically acceptable salt thereof, preparation method and application 中国医学科学院医药生物技术研究所 2024-06-11 — — CN claimed
CN-110023309-B Indazole derivatives as glucagon receptor antagonists 詹森药业有限公司 2022-08-09 — — CN claimed
US-20200377462-A1 INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2020-12-03 — — US claimed
US-10774048-B2 Indazole derivatives useful as glucagon receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2020-09-15 — — US claimed
EP-3510026-B1 INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2020-08-12 — — EP claimed
EP-3510028-B1 INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2020-08-05 — — EP claimed
US-20190218186-A1 INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2019-07-18 — — US claimed
EP-3510028-A1 INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS Janssen Pharmaceutica NV (BE) 2019-07-17 — — EP claimed
EP-3510026-A1 INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS Janssen Pharmaceutica NV (BE) 2019-07-17 — — EP claimed
US-10000473-B2 Indazole derivatives useful as glucagon receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2018-06-19 — — US claimed
US-20040122063-A1 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-24 — — US claimed
EP-1423386-A1 THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-02 — — EP claimed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 — — EP claimed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 — — EP claimed
WO-2003022842-A1 THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-20 — — WO claimed
EP-1270557-A1 ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-01-02 — — EP claimed
US-20020165222-A1 Protease inhibitors SMITHKLINE BEECHAM CORPORATION 2002-11-07 — — US claimed
EP-1153022-A4 PROTHEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2002-03-27 — — EP claimed
EP-1153022-A1 PROTHEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-14 — — EP claimed
WO-2000049011-A1 PROTHEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2000-08-24 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774048-B2 Indazole derivatives useful as glucagon receptor antagonists GPR119, GLP1R, GIPR CYP2A6 917/4885CYP1A2 296/4885TDP1 4587/4885
US-20200377462-A1 INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS GPR119, GLP1R, GIPR CYP2A6 917/4885CYP1A2 296/4885TDP1 4587/4885
US-20020165222-A1 Protease inhibitors CTSK, CTSZ, CTSE CYP2A6 1126/4885CYP1A2 2516/4885TDP1 2192/4885
US-20190218186-A1 INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS GPR119, GLP1R, GIPR CYP2A6 917/4885CYP1A2 296/4885TDP1 4587/4885
US-10000473-B2 Indazole derivatives useful as glucagon receptor antagonists GPR119, GLP1R, GIPR CYP2A6 917/4885CYP1A2 296/4885TDP1 4587/4885
US-20040122063-A1 Ethylenediamine derivatives ECE1, F2, ECE2 CYP2A6 1405/4885CYP1A2 273/4885TDP1 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.